With a multinational medical device company in China; Vertical monopoly case” The dust has settled, and the once unnoticed biomedical polymer materials have attracted widespread attention, further demonstrating their market potential. At present, multinational enterprises such as Johnson&Johnson Medical and Braun Medical, due to their technological advantages, occupy a dominant position in the biomedical polymer material market in China.
According to reporters, biomedical polymer materials are a special type of functional polymer material commonly used for diagnosis, treatment, replacement or repair, synthesis or regeneration of damaged tissues and organs in living organisms. With increasing public attention to physical health, the market demand for biomaterials is gradually increasing.
Due to the wide variety of biomedical polymer materials in the market, multinational enterprises are unable to meet all market demands, which provides domestic enterprises with ample room to leverage. At present, there are a total of 8 listed companies in China that are involved in this field, among which Guanhao Biological and Dikang Pharmaceutical have maintained a leading position in research and development in this field.
&Ldquo; Although the current scale of biomedical device materials is relatively small, they are indeed needed by consumers& Rdquo; Yu Mingde, President of the China Pharmaceutical Enterprise Management Association, pointed out in an interview with the media.
The "12th Five Year Plan for the Development of the New Materials Industry" released by the Ministry of Information Industry clearly proposes to strengthen research on biomedical materials, improve material biocompatibility and chemical stability, vigorously develop high-performance, low-cost biomedical high-end materials and products, and promote the upgrading and upgrading of medical device basic materials& Ldquo; Twelfth Five Year Plan; Megaproject also include special projects for biomedical materials.
&Ldquo; Compared to polymer materials, biomedical polymer materials can better integrate with human tissues, meet biomechanical requirements, and significantly reduce the degree of harm caused by material substances to the human body& Rdquo; An industry analyst told reporters.
According to the current industry development trend, biomedical polymer materials mainly include lipid materials such as polylactic acid, Polybutylene succinate, and material materials such as nickel titanium stent and stainless steel stent. Among them, lipids have heat resistance, compatibility, degradability and other properties, which are suitable for the production of films, Bin bag and other materials; Material materials have good Compressibility, tensile strength, hardness and other properties, and are commonly used in the production of medical devices.
According to the reporter, China started late in the field of polymer materials for artificial organs, such as heart valves, Artificial kidney, Artificial skin, etc., and has invested heavily in primary tissue engineering scaffold materials. A huge challenge encountered in the development of medical polymer materials is the issue of anti thrombotic properties. Yin Jinghua, a researcher at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, believes that:; Surface modification of polyolefin materials through chemical treatment, plasma, UV, and irradiation is one of the most effective methods to improve their blood compatibility& Rdquo;
According to Transparency Market Research&quo; Transparency Market Research; A newly released market research report states that global demand for medical polymer materials will continue to rise at a compound annual growth rate of 5.6% from 2012 to 2018; Compared to other sectors in the medical device industry, the revenue growth rate in this field is clearly faster, with an expected compound annual growth rate of 8.4%; The aging population is the main driving factor, and it is reported that by 2050, more than 16% of the global population will be over 65 years old. Two local enterprises lead the way; Second Group; As a leader in the field of biomedical polymer materials in China; Second Group; Our companies, Guanhao Biotechnology and Dikang Pharmaceutical, have established advantages in their respective fields.
At present, the main products produced by Guanhao Biotechnology are membrane products, including biological dural (spinal) membrane patches (meningeal reconstruction), thoracic and general surgical repair membranes (body membrane reconstruction), and sterile biological wound protection membranes (de membrane reconstruction). The meningeal construction market accounts for over 40% of the total main business revenue, accounting for 93.30%, and is the main source of the company's current operating income.
In this field, Guanhao Biotechnology is facing competition from multinational corporations. Its main competitors in this field are internationally renowned large pharmaceutical companies such as Johnson&Johnson and Braun Medical, among which Johnson&Johnson holds a 20% share in the meningeal construction market.
Although Guanhao Biotechnology has performed well in the face of competition from multinational corporations, many analysts believe that the high proportion of revenue poses enormous risks to the company. Once major fluctuations in the Neurosurgery medical market lead to shrinking demand, the company's operating income will be deeply affected. In order to maintain its own advantages, Guanhao Biology is conducting diversified research and development in this field.
At present, the company is increasing its research and development of plastic and beauty products. A relevant person from the board office of Guanhao Biotechnology told reporters:; When we went public, we mentioned the future development towards plastic surgery and beauty. Many hospitals now have specialized plastic surgery and beauty departments, and there is a great market demand& Rdquo;
The tissue patches used for plastic surgery and beauty are also obtained from edible animal tissues through a tissue processing platform. The biggest feature is that it can directly enter the human body, inducing regeneration and passive degradation. The market promotion of a series of products such as gynecology and plastic surgery has also been recognized as the company's future growth focus by the market.
And another leading enterprise&flash& Flash; Dikang Pharmaceutical has completely shifted its strategic focus to biomedical polymer materials. It is reported that due to the drug retail terminal&flash& Flash; Peace Chain has poor performance, and Dikang has chosen to withdraw from the pharmaceutical retail industry. Currently undergoing major asset restructuring, the company has focused its main business on the pharmaceutical and medical device industries this year.
&Ldquo; Biomaterials were converted from our 863 project a long time ago, and the technology has been relatively mature from the beginning to the conversion process& Rdquo; Jiang Li, Secretary of the Board of Directors of Dikang Pharmaceutical, told reporters.
According to reporters, Dikang Pharmaceutical mainly produces biomedical polymer materials such as absorbable medical membranes and absorbable fracture internal fixation screws. The absorbable medical membrane adopts ultra-high molecular weight absorbable poly-DL-lactic acid material, which has good adhesion and flexibility, and can effectively isolate surgical wounds; The absorbable fracture internal fixation screw is made of ultra-high molecular weight poly-DL-lactic acid material, which is completely biodegradable and has an elastic modulus similar to that of cancellous bone.
It is reported that after optimizing the industrial structure in the first half of this year, Dikang Pharmaceutical has concentrated its resources on the production and sales of two major product groups: digestive system drugs and biomedical materials and devices; On June 24th, the board of directors approved the use of their own funds to purchase approximately 60 acres of land for future investment in the construction of high-tech biomedical material research and development production bases. (Extracted from Medical Economics News)
